- Home
- FHTX vs ABSI Comparison
FHTX vs ABSI Comparison
Compare FHTX & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- ABSI
- Stock Information
- Founded
- FHTX 2015
- ABSI 2011
- Country
- FHTX United States
- ABSI United States
- Employees
- FHTX N/A
- ABSI N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- FHTX Health Care
- ABSI Health Care
- Exchange
- FHTX Nasdaq
- ABSI Nasdaq
- Market Cap
- FHTX 513.7M
- ABSI 457.6M
- IPO Year
- FHTX 2020
- ABSI 2021
- Fundamental
- Price
- FHTX $7.72
- ABSI $2.55
- Analyst Decision
- FHTX Strong Buy
- ABSI Strong Buy
- Analyst Count
- FHTX 5
- ABSI 6
- Target Price
- FHTX $16.00
- ABSI $8.67
- AVG Volume (30 Days)
- FHTX 131.6K
- ABSI 1.5M
- Earning Date
- FHTX 11-04-2024
- ABSI 11-12-2024
- Dividend Yield
- FHTX N/A
- ABSI N/A
- EPS Growth
- FHTX N/A
- ABSI N/A
- EPS
- FHTX N/A
- ABSI N/A
- Revenue
- FHTX $25,515,000.00
- ABSI $4,207,000.00
- Revenue This Year
- FHTX N/A
- ABSI $9.36
- Revenue Next Year
- FHTX $8.77
- ABSI $198.59
- P/E Ratio
- FHTX N/A
- ABSI N/A
- Revenue Growth
- FHTX N/A
- ABSI N/A
- 52 Week Low
- FHTX $2.70
- ABSI $1.35
- 52 Week High
- FHTX $10.25
- ABSI $6.72
- Technical
- Relative Strength Index (RSI)
- FHTX 42.02
- ABSI 24.46
- Support Level
- FHTX $7.33
- ABSI $2.45
- Resistance Level
- FHTX $9.33
- ABSI $4.47
- Average True Range (ATR)
- FHTX 0.72
- ABSI 0.28
- MACD
- FHTX -0.13
- ABSI -0.15
- Stochastic Oscillator
- FHTX 16.46
- ABSI 4.96
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.